Journal of Food and Nutrition Research
ISSN (Print): 2333-1119 ISSN (Online): 2333-1240 Website: http://www.sciepub.com/journal/jfnr Editor-in-chief: Prabhat Kumar Mandal
Open Access
Journal Browser
Go
Journal of Food and Nutrition Research. 2014, 2(8), 485-490
DOI: 10.12691/jfnr-2-8-9
Open AccessArticle

Effect of Corn Peptides in Combination with Exercise on Weight Reduction, Plasma Lipid, Chemerin and Lp-PLA2 in Overweight and Obese Females

Yin Wu1, Liang Yin2, Xiaohui Wang2, and Shujie Lou2

1Department of Computer and Statistics, Shanghai University of Sport, Shanghai, China

2Department of Sport Science, Shanghai University of Sport, Shanghai, China

Pub. Date: August 13, 2014

Cite this paper:
Yin Wu, Liang Yin, Xiaohui Wang and Shujie Lou. Effect of Corn Peptides in Combination with Exercise on Weight Reduction, Plasma Lipid, Chemerin and Lp-PLA2 in Overweight and Obese Females. Journal of Food and Nutrition Research. 2014; 2(8):485-490. doi: 10.12691/jfnr-2-8-9

Abstract

Our previous work has demonstrated better weight reduction and plasma lipid improvement roles of corn peptides (CP) in combination with aerobic exercise than aerobic exercise in obese rats, the purpose of this paper is to explore if the better effectiveness of CP combined with exercise also exist in overweight and slight obese young females and to determine the possible role of adipokine chemerin and inflammation factor lipoprotein-associated phspholipase A2 (Lp-PLA2). Twenty-six young female (18-21 years old, body fat percentage: 29.15%±2.71% and body mass index (BMI): 23.92±1.78) were allocated randomly to four groups: exercise 1 group (E1, n=6), CP+E1 group (n=7), E2 group (n=6) and CP+E2 group (n=7). The females in E1 and CP+E1 groups did 1 hour aerobics 3 times a week, while the same aerobics were done but 5 times a week by E2 and CP+E2 groups. The exercise lasts for four weeks and 10 g of CP were taken orally by the females in the two CP groups every night after meal. Similar power placebo was administered to the non-CP treated females. The diet of these females kept unchanged during the 4 weeks. The body weight, BMI, body fat percentage and plasma lipid parameters including triglyceride (TG), total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), apolipoprotein a (Apo-A), apolipoprotein b (Apo-B) and the ratios of LDL-C/HDL-C and Apo-B/Apo-A as well as plasma levels of chemerin and Lp-PLA2 were determined pre and post 4 weeks. Compared to E1 group, all the above parameters did not change in CP+E1 group after 4 weeks. Except for an obvious reduction of body fat percentage (from 29.44%±2.65% to 27.93%±2.56% vs from 27.95%±3.38% to 27.47%±3.88%, p<0.05) were found in CP+E2 group, other changes were still not observed compare with that of E2. It’s worth noting that obvious reduction of chemerin was found in individuals with abnormal lipid parameters return to normal and no change of chemerin was showed in a female whose abnormal lipid index kept stable after treatment with CP combined with exercise. In conclusion, only when frequent aerobic exercise was performed did CP in combination with aerobic exercise promote significantly the decrease of body fat percentage in overweight and slight obese females. The fat loss resulted from CP in combination with exercise is not related to the plasma levels of chemerin and Lp-PLA2, which might be attributed to no change of blood lipid parameters within normal ranges in overweight and slight obese females. Although no difference of chemerin between groups, changes of plasma chemerin in individual females with abnormal lipid parameters suggested that CP in combination with exercise might reverse the abnormal plasma levels of TG, TC and LDL-C by decreasing the plasma levels of chemerin.

Keywords:
CP chemerin body fat percentage Lp-PLA2

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Xiuxia Li LH, Longjia Chen: In vitro antioxidant activity of protein hydrolysates prepared from corn gluten meals. Journal of the Science of Food and Agriculture 2008, 88(9):1660-1668.
 
[2]  Yang Y, Tao G, Liu P, Liu J: Peptide with angiotensin I-converting enzyme inhibitory activity from hydrolyzed corn gluten meal. J Agric Food Chem 2007, 55(19):7891-7895.
 
[3]  Ma ZL, Zhang WJ, Yu GC, He H, Zhang Y: The primary structure identification of a corn peptide facilitating alcohol metabolism by HPLC-MS/MS. Peptides 2012, 37(1): 138-143.
 
[4]  Melo-Silveira RF, Fidelis GP, Viana RL, Soeiro VC, Silva RA, Machado D, Costa LS, Ferreira CV, Oliveira Rocha HA: Antioxidant and antiproliferative activities of methanolic extract from a neglected agricultural product: corn cobs. Molecules 2014, 19(4): 5360-5378.
 
[5]  Bong HY, Kim JY, Jeong HI, Moon MS, Kim J, Kwon O: Effects of corn gluten hydrolyzates, branched chain amino acids, and leucine on body weight reduction in obese rats induced by a high fat diet. Nutr Res Pract 2010, 4(2): 106-113.
 
[6]  Shunli Wang XL, Ru Wang, Xiaohui Wang, Shujie Lou: Effect of corn peptide ingestion and exercise on protein metabolism in skeletal muscle of obese rats and its possible mechanism. Acta Nutrimenta Sinica [in chinese] 2013, 35(6): 540-544.
 
[7]  Fulop P, Seres I, Lorincz H, Harangi M, Somodi S, Paragh G: Association of chemerin with oxidative stress, inflammation and classical adipokines in non-diabetic obese patients. J Cell Mol Med 2014.
 
[8]  Lorincz H, Katko M, Harangi M, Somodi S, Gaal K, Fulop P, Paragh G, Seres I: Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects. Clin Endocrinol (Oxf) 2013.
 
[9]  Sledzinski T, Korczynska J, Hallmann A, Kaska L, Proczko-Markuszewska M, Stefaniak T, Sledzinski M, Swierczynski J: The increase of serum chemerin concentration is mainly associated with the increase of body mass index in obese, non-diabetic subjects. J Endocrinol Invest 2013, 36(6): 428-434.
 
[10]  Schultz S, Beck-Sickinger AG: Chemerin and vaspin: possible targets to treat obesity? ChemMedChem 2013, 8(4): 549-559.
 
[11]  Wang D, Yuan GY, Wang XZ, Jia J, Di LL, Yang L, Chen X, Qian FF, Chen JJ: Plasma chemerin level in metabolic syndrome. Genet Mol Res 2013, 12(4): 5986-5991.
 
[12]  Rourke JL, Dranse HJ, Sinal CJ: Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev 2013, 14(3): 245-262.
 
[13]  Yang M, Yang G, Dong J, Liu Y, Zong H, Liu H, Boden G, Li L: Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med 2010, 58(7): 883-886.
 
[14]  Yu S, Zhang Y, Li MZ, Xu H, Wang Q, Song J, Lin P, Zhang L, Liu Q, Huang QX et al: Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients. Chin Med J (Engl) 2012, 125(19): 3440-3444.
 
[15]  Herova M, Schmid M, Gemperle C, Loretz C, Hersberger M: Low dose aspirin is associated with plasma chemerin levels and may reduce adipose tissue inflammation. Atherosclerosis 2014, 235(2): 256-262.
 
[16]  Ress C, Tschoner A, Engl J, Klaus A, Tilg H, Ebenbichler CF, Patsch JR, Kaser S: Effect of bariatric surgery on circulating chemerin levels. Eur J Clin Invest 2010, 40(3): 277-280.
 
[17]  Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R: Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26(11): 2523-2529.
 
[18]  Jiaxing Liu XZ, Yongwen Qin, et al: lipoprotein-associated phospholipase A2 as a predictor for severity of coronary atherosclerosis (in Chinese) Acad J Sec Mil Med Univ 2006, 27(4): 391-395.
 
[19]  Koenig W, Twardella D, Brenner H, Rothenbacher D: Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006, 26(7): 1586-1593.
 
[20]  Tzotzas T, Filippatos TD, Triantos A, Bruckert E, Tselepis AD, Kiortsis DN: Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Nutr Metab Cardiovasc Dis 2008, 18(7): 477-482.
 
[21]  Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, Seeley RJ: Hypothalamic mTOR signaling regulates food intake. Science 2006, 312(5775): 927-930.
 
[22]  Layman DK, Walker DA: Potential importance of leucine in treatment of obesity and the metabolic syndrome. J Nutr 2006, 136(1 Suppl): 319S-323S.
 
[23]  Stefanov T, Bluher M, Vekova A, Bonova I, Tzvetkov S, Kurktschiev D, Temelkova-Kurktschiev T: Circulating chemerin decreases in response to a combined strength and endurance training. Endocrine 2014, 45(3): 382-391.
 
[24]  Lee MK, Chu SH, Lee DC, An KY, Park JH, Kim DI, Kim J, Hong S, Im JA, Lee JW et al: The association between chemerin and homeostasis assessment of insulin resistance at baseline and after weight reduction via lifestyle modifications in young obese adults. Clin Chim Acta 2013, 421: 109-115.
 
[25]  Kim SH, Lee SH, Ahn KY, Lee DH, Suh YJ, Cho SG, Choi YJ, Lee SY, Hong SB, Kim YS et al: Effect of lifestyle modification on serum chemerin concentration and its association with insulin sensitivity in overweight and obese adults with type 2 diabetes. Clin Endocrinol (Oxf) 2014, 80(6): 825-833.
 
[26]  da Silva IT, Timm Ade S, Damasceno NR: Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study. Lipids Health Dis 2013, 12: 19.
 
[27]  Hirschler V, Merono T, Maccallini G, Gomez Rosso L, Aranda C, Brites F: Association of lipoprotein-associated phospholipase A(2) activity with components of the metabolic syndrome in apparently healthy boys. Cardiovasc Hematol Agents Med Chem 2011, 9(2): 78-83.